Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SS was diagnosed according to the SS European Criteria~* chronic symptoms of burning, foreign body sensation, itching in both eyes~* daily need of artificial tears~* abnormal Schirmer (ST) I test \< 5mm or rose Bengal staining (RBS) ≥ 4, or break up time (BUT) \< 5 seconds.~Exclusion Criteria:~* any structural abnormalities (lid scarring, entropion, trichiasis, etc.)~* any inflammation or active structural change in the iris or anterior chamber~* glaucoma~* previous eye surgery or punctual occlusion~* use of any other topical medication other than artificial tears~* any systemic or topical antibacterial or antiinflammatory drug treatment 90 days before study entry~* contact lens wearer~* the presence of any corneal infection~* any corneal diseases (marginal ulcer, opacity, scar, bullous keratopathy, conjunctivochalasis, symblepharon or tumor)~* pregnancy~* change in the immunosuppressive systemic therapy 90 days before study entry

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- tacrolimus (Type: ACTIVE_COMPARATOR): tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
- Olive Oil (Type: PLACEBO_COMPARATOR): All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).